News Sanofi, Regeneron flesh out COPD data with Dupixent Sanofi and Regeneron have built their case for Dupixent as a first biological therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (AT
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face